anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Acute kidney injury (AKI) resulting from ureteral stones in the emergency department is typically accompanied with anxiety and sleep issues in patients, which can have adverse effects on their mental health and quality of life. Cognitive behavioural therapy (CBT) is helpful in improving mental health and sleep. This work aims to analyse the effects of CBT on mental health and sleep of AKI patients caused by ureteral calculi in the emergency department.
METHODS: The clinical data of patients with AKI caused by ureteral calculi in the emergency department of our hospital from February 2021 to February 2023 were retrospectively analyzed. The patients were divided into the control group (routine nursing) and observation group (cognitive behavioural nursing) according to the different nursing methods of data recording. Propensity Score Matching (PSM) was used to balance the confounding factors of the two groups. After matching, the State Trait Anxiety Inventory (STAI), Insomnia Severity Index (ISI), Mishel Uncertainty in Illness Scale-Adult (MUIS) and 36-Item Short-Form Health Survey (SF-36) were compared between the two groups.
RESULTS: After matching at a ratio of 1:1, 130 patients were included in the observation group and the control group, with 65 cases in each group. No significant difference was observed in STAI, ISI, MUIS and SF-36 scores between the two groups before nursing (p > 0.05). After nursing, the STAI, ISI and MUIS scores of the observation group were lower than those of the control group (p < 0.05). Furthermore, the SF-36 score of the observation group was higher than that of the control group (p < 0.05).
CONCLUSIONS: Cognitive behavioural nursing for patients with AKI caused by ureteral calculi in the emergency department may help in retrieving patients' anxiety, reducing the severity of disease uncertainty and insomnia, improving the quality of life of patients and providing theoretical reference for clinical practice.
The invention discloses burn and scald ointment. The burn and scald ointment comprises the following raw materials in parts by weight: 600-700 parts of calcined gypsum, 625-725 parts of edible rapeseed oil, 25-30 parts of camphor, 30-35 parts of borneol, 15-30 parts of oxytetracycline and 20-25 parts of furazolidone. The invention also discloses a preparation method of the burn and scald ointment. The preparation method comprises the following steps of: putting the raw materials except for the edible rapeseed oil in a container in proportion and mixing at a normal temperature, soaking the mixture by using the edible rapeseed oil, and mixing into paste, thus obtaining the burn and scald ointment. The burn and scald ointment has the advantages that the sources of raw materials are wide, the preparation process is simple, the curative effect is good, the burn and scald ointment is easy to clean and non-sticky and falls off without residues after being wetted. The preparation method is simple and only needs ordinary grinding and mixing equipment.
PURPOSE: A neutraceutical composition containing mixture extract of Phellinus linteus mycelium and cultured wild ginseng roots for anti-cancer is provided. CONSTITUTION: A pharmaceutical composition for anti-cancer contains mixture extract of Phellinus linteus mycelium powder and cultured wild ginseng roots mixed in a weight ratio of 1:1-5:1. The mixture extract is isolated using water, organic solvent or mixture solvent thereof. The organic solvent is C1-C4 alcohol, ethyl acetate, methylene chloride, or chloroform. The ethanol is 40-60% ethanol. A pharmaceutical composition for preventing or treating cancer contains the mixture extract as an active ingredient.
Neurovascular compression syndrome (NVCS), characterized by cranial nerve compression due to adjacent blood vessels at the root entry zone, frequently presents as trigeminal neuralgia (TN), hemifacial spasm (HFS), or glossopharyngeal neuralgia (GN). Despite its prevalence in NVCS assessment, Magnetic Resonance Tomographic Angiography (MRTA)'s limited sensitivity to small vessels and veins poses challenges. This study aims to refine vessel localization and surgical planning for NVCS patients using a novel 3D multimodal fusion imaging (MFI) technique incorporating computed tomography angiography and venography (CTA/CTV). A retrospective analysis was conducted on 76 patients who underwent MVD surgery and were diagnosed with single-site primary TN, HFS, or GN. Imaging was obtained from MRTA and CTA/CTV sequences, followed by image processing and 3D-MFI using FastSurfer and 3DSlicer. The CTA/CTV-3D-MFI showed higher sensitivity than MRTA-3D-MFI in predicting responsible vessels (98.6% vs. 94.6%) and NVC severity (98.6% vs. 90.8%). Kappa coefficients revealed strong agreement with MRTA-3D-MFI (0.855 for vessels, 0.835 for NVC severity) and excellent agreement with CTA/CTV-3D-MFI (0.951 for vessels, 0.952 for NVC). Resident neurosurgeons significantly preferred CTA/CTV-3D-MFI due to its better correlation with surgical reality, clearer depiction of surgical anatomy, and optimized visualization of approaches (p < 0.001). Implementing CTA/CTV-3D-MFI significantly enhanced diagnostic accuracy and surgical planning for NVCS, outperforming MRTA-3D-MFI in identifying responsible vessels and assessing NVC severity. This innovative imaging modality can potentially improve outcomes by guiding safer and more targeted surgeries, particularly in cases where MRTA may not adequately visualize crucial neurovascular structures.
This is a Phase I, randomized, double-blind, placebo controlled dose escalation trial to evaluate NTM-1632 in three dose cohorts (A: 0.033 mg/kg, B: 0.165 mg/kg, and C: 0.33 mg/kg). NTM-1632 is a mixture of three monoclonal antibodies designed to treat botulinum neurotoxin BoNT/B poisoning in adults. Dose cohorts A, B, and C will be randomized 2:6, placebo:therapeutic, with a total study population of 24. The study duration is projected to be approximately 8 months, with subject participation in cohort A being approximately 13 weeks, and subject participation in cohort B and C being approximately 17weeks. The primary objectives of this study are to assess the safety and tolerability of escalating doses of NTM-1632 administered intravenously in healthy adults. The secondary objectives are to 1) assess the pharmacokinetic characteristics of NTM-1632 following a single intravenous administration and 2) assess the immunogenicity of NTM-1632 following a single intravenous administration.
N-acetylcysteine (NAC) is an FDA-approved drug that has been used in multiple conditions to mitigate oxidative stress. The study investigators' lab and others have shown that NAC provides neuroprotection either alone or in combination with hypothermia when given within 1-6 hrs of insult in animal models of HI injury. However, in neonatal rats subjected to severe hypoxic ischemic insult, NAC + hypothermia did not neuroprotect males as well as females. The study investigators and others determined that the majority of HIE infants are insufficient or deficient in 25(OH)vitamin D, a critical neurosteroid that also augments synthesis of an important antioxidant, glutathione. By adding active, low-dose 1,25-dihydoxy-Vitamin D3 to NAC (NVD), with a 1 hour delay after starting hypothermia, and repeated daily for 14 days in neonatal rat HI model, the study investigators significantly improved severity of brain injury over hypothermia alone in both sexes. Importantly, NVD also significantly improved functional outcomes of strength, sensorimotor and memory functioning 6 weeks after HI, even in male rats with the most severe brain pathology.

NAC and active vitamin D are FDA approved and are safe even in very sick newborns. In the study investigators' trial of NAC in maternal chorioamnionitis, comprehensive physiologic monitoring in preterm and term infants exposed to intrauterine inflammation demonstrated no significant differences in cerebral blood flow, oxygenation, or left ventricular function in infants treated with NAC or saline.

The primary objective of this study in human neonates after HIE birth treated with the standard hypothermia protocol, is to determine the unique pharmacokinetic (PK) parameters of NAC and vitamin D during hypothermia and after rewarming, verify the central nervous system (CNS) effect of NVD on the pharmacodynamic target, reduced glutathione, and determine the duration of CNS effect. The study investigators used low dose NAC (Acetadote, 25-40 mg/kg/dose) every 12 hours and Vitamin D3 (Calcitriol, 0.03 to 0.1microgram/kg) every 12-24 hours, infused IV for 10 days in a dose escalating study. The study investigators determined PK parameters and plasma oxidative stress markers during day 1 of life while hypothermic, and day 5 of life during normothermia (24-36 hours after rewarming). To establish effective dosing of NVD based directly on CNS effect, CNS metabolites were quantified with magnetic resonance spectroscopy (MRS) before and immediately after NVD dosing on DOL 5, infusing NVD during the routine MRI for HIE. In a subset of 10 infants the delayed effects of NVD on CNS metabolomics were determined by MRS between 2-6h after NVD dosing on DOL 5. Development was followed for \>24months.
The principal and potentially serious toxic effects of mercaptopurine are bone marrow toxicity and hepatotoxicity (see WARNINGS and PRECAUTIONS). 

Hematologic: The most frequent adverse reaction to mercaptopurine is myelosuppression. The induction of complete remission of acute lymphatic leukemia frequently is associated with marrow hypoplasia. Patients without TPMT enzyme activity (homozygous-deficient) are particularly susceptible to hematologic toxicity, and some patients with low or intermediate TPMT enzyme activity are more susceptible to hematologic toxicity than patients with normal TPMT activity (see WARNINGS: Bone Marrrow Toxicity), although the latter can also experience severe toxicity. Maintenance of remission generally involves multiple-drug regimens whose component agents cause myelosuppression. Anemia, leukopenia, and thrombocytopenia are frequently observed. Dosages and also schedules are adjusted to prevent life-threatening cytopenias. 

Renal: Hyperuricemia and/or hyperuricosuria may occur in patients receiving mercaptopurine as a consequence of rapid cell lysis accompanying the antineoplastic effect. Renal adverse effects can be minimized by increased hydration, urine alkalinization, and the prophylactic administration of a xanthine oxidase inhibitor such as allopurinol. The dosage of mercaptopurine should be reduced to one third to one quarter of the usual dose if allopurinol is given concurrently. 

Gastrointestinal: Intestinal ulceration has been reported. Nausea, vomiting, and anorexia are uncommon during initial administration, but may increase with continued administration. Mild diarrhea and sprue-like symptoms have been noted occasionally, but it is difficult at present to attribute these to the medication. Oral lesions are rarely seen, and when they occur they resemble thrush rather than antifolic ulcerations. 

Miscellaneous: The administration of mercaptopurine has been associated with skin rashes and hyperpigmentation. Alopecia has been reported. 

Drug fever has been very rarely reported with mercaptopurine. Before attributing fever to mercaptopurine, every attempt should be made to exclude more common causes of pyrexia, such as sepsis, in patients with acute leukemia. Oligospermia has been reported.
The Part1-A of groups take Telmisartan once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
Adults older than 60 years of age will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
The invention comprises a lipid nano carrier based nanogel formulation of an active ingredient and method of their preparation. The formulation is specifically useful for dermal delivery or topical application of drugs, which may be a hydrophilic drug including 5-fluorouracil (5-FU) and acyclovir, or a hydrophobic drug such as isotretinoin. The invention is illustrated by a lipid nano carrier based nanogel formulation of 5-FU. A lipid nano carrier based nanogel formulation comprising 5- FU in a concentration of 0.001% to 10% w/w. A method of preparing lipid nano carrier based nanogel formulation of an active ingredient comprises the steps of: preparation of drug loaded vesicular lipid carrier dispersion, wherein the surface of vesicles of the lipid carrier contains a surfactant, probe sonicating the drug loaded vesicular lipid carrier dispersion of step (a.) to prepare a lipid nano carrier dispersion in nanometric size range, concentrating the lipid nano carrier dispersion in nanometric range by steps of subjecting the lipid nano carrier dispersion in nanometric size range of step (b.) either to (i) rotary evaporation, or (ii) freeze drying with or without a cryoproetctant, preparation of hydrophilic gel; and mixing of lipid nano carrier dispersion of step (c.) with hydrophilic gel of step (b) to form a lipid nano carrier based nanogel formulation.
The invention discloses a galium verum extract product with estrogen activity, a preparing method thereof and applications of the extract product, and belongs to the technical field of Chinese herbal medicines. The method includes following steps: (1) subjecting whole herb coarse powder of galium verum to ultrasonic wave extraction and reflux extraction by using ethanol having a concentration of 60-80%, filtering the obtained extract liquid, and concentrating the extract liquid under vacuum to recover the ethanol to obtain an extract; and (2) dissolving the extract with ethanol having a concentration of 8-12%, adding into a macroporous adsorption resin column, allowing the column to stand, washing by ethanol having a concentration of 15-25% firstly to remove impurities, eluting with ethanol having a concentration of 50-70%, collecting ethanol eluate, concentrating the ethanol eluate under vacuum to recover the ethanol, and drying at a low temperature. The preparing method has advantages of simple processes, short period, high yield, and the like. The prepared galium verum extract product mainly comprises total flavonoid compounds. The content of the total flavonoid compounds is higher than 57%. The total flavonoid compounds mainly comprise luteoloside. The prepared galium verum extract product can stimulate mouse uterus growth, promote weight gain and increase the estrogen level.
The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.
OBJECTIVES: I. Determine the safety and maximum tolerated dose of interleukin-2 (IL-2) and stem cell factor (SCF) following autologous peripheral blood stem cell transplantation in patients with non-Hodgkin's lymphoma or advanced breast cancer. II. Determine the effectiveness of filgrastim (G-CSF) and SCF as mobilizing agents in these patients.

OUTLINE: This is a dose escalation study of stem cell factor (SCF). Patients receive filgrastim (G-CSF) subcutaneously (SC) followed by SCF SC daily for 7-10 days. Beginning on the fifth day of G-CSF and SCF injections, peripheral blood stem cells (PBSC) are collected over several days. PBSC are later reinfused and patients receive G-CSF SC daily until hematopoietic recovery. At least 30 days but no later than 110 days following transplant, patients who did not experience adverse reactions to SCF during mobilization begin posttransplant immunotherapy. Patients receive interleukin-2 SC daily and SCF SC 3 times weekly for 6 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SCF during posttransplant immunotherapy until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities. Patients are followed at 1 week, every 3 months for 1 year, and then every 6 months thereafter.

PROJECTED ACCRUAL: A maximum of 27 patients will be accrued for this study within 1-1.5 years.
The invention provides an information processing device, an information processing method, and an information processing system. The information processing device comprises a report acquisition unit, a related area acquisition unit, a determining unit, and a control display unit. The report acquisition unit is suitable for acquiring report information, which comprises a concerned area of a medial image and annotation information related to the concerned area. The related area is used to acquire the area related to the concerned area in the medical image. The determining unit is used to determine the display position of the display area of the annotation information, and is used to prevent the display area of the annotation information overlapped with the related area. The display control unit is used to display the medical image of the annotation information, and then the annotation information is displayed on the display position determined by the display area of the display unit.
Experimental Group 2 - patients will apply the infuse since the begging of radiodermatitis, three times a day. The dose of 2,5% was determined before in a Phase II study. Radiodermatitis grade and intensity is going to be evaluated. Topical application of the infuse is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
NEW MATERIAL:A compound shown by the formula I (R1-R4 are H, or lower alkyl; X is H, lower alkoxy, halogen, or lower alkyl/ Y is halogen; Z is acid residue). EXAMPLE:N-(3,4-Dimethoxyphenethy)phthalimide. USE:A metabolic activator. Useful as a remedy or diagnosticum for metabolic diseases. Useful for improving cerebral local blood circulation, for remedying various cerebral diseases, cardiac muscle-activating circulatory organs, etc. Also useful as a contrast medium for X-ray photographing. PREPARATION:A compound shown by the formula II is reacted with an alkylating agent such as R2Z, R3Z, R4Z, etc. For example, the compound is reacted with a lower alkyl chloride or iodide in an aprotic polar solvent sch as acetone, methyl ethyl ketone, etc., or with a hydrohalogenic acid in a polar solvent such as methanol, etc. to give a compound shown by the formula I.
The invention provides double-unit preparation containing simvastatin and niacin, which are bilayer tablets or compound capsules containing two tablets. The double-unit preparation comprises a simvastatin unit and a niacin unit, wherein the two medicine-containing units are isolated. The simvastatin unit contains 5, 10 or 15 mg of simvastatin and a pharmaceutically acceptable excipient. The niacin unit contains 500, 750 or 1,000 mg of niacin, a sustained-release carrier, a bonding agent, a lubricating agent and another necessary pharmaceutically application excipient. The sustained-release carrier may be cellulose with high expansibility and gelling property or derivatives thereof. The double-unit preparation containing simvastatin and niacin can be used for preparing medicines for regulating blood fat.
A portable wireless-enabled health monitoring apparatus with multiple sensors to measure vital signs and other bodily health conditions is disclosed. In various embodiments, the apparatus may have a shape that is a flattened sphere having an upper and lower portion. An upper portion of the apparatus may itself contain sensors and/or reveal additional sensors to measure vitals and other bodily health information. The health monitoring apparatus may connect to a wireless device (e.g, a smart phone) and be controlled via an accompanying mobile application. The mobile device may communicate with a telemedicine service and/or online platform that is accessible by both the patient and the care provider. In various embodiments, the apparatus includes, but is not limited to, the capability for electrocardiogram monitoring, pulse oximetry monitoring, heart rate monitoring, blood pressure monitoring, temperature monitoring, and stethoscope recording and monitoring.
BACKGROUND AND AIMS: As global life expectancy rises and gastrointestinal tumor incidence increases, more elderly patients are undergoing endoscopic submucosal dissection (ESD) for tumor treatment. The current situation highlights the importance of sarcopenia assessment before ESD. This systematic review and meta-analysis aim to assess sarcopenia's role in predicting post-ESD adverse outcomes in the elderly.
METHODS: We conducted a systematic review and meta-analysis to investigate the impact of sarcopenia on the prognosis of elderly patients undergoing ESD treatment. A comprehensive search was conducted across three databases (PubMed, Embase, Web of Science). We were using NEWCASTLE-OTTAWA ASSESSMENT SCALE for risk of bias assessment. The data were synthesized using Review Manager 5.3.
RESULTS: A total of 9 reports were identified, analyzing 7 indicators, with a combined sample size of 6044. Through a series of analyses, we have derived several highly credible research findings: the overall OR and 95% CI for gastric and colorectal post-ESD perforation between sarcopenia and nonsarcopenia groups were 1.34 [0.92, 1.97], for CTCAE grade > 2 was 2.65 [1.45, 4.82], for upper gastrointestinal post-ESD pneumonia were 1.97 [1.30, 2.99], and for gastric post-ESD mortality within 5 years were 2.96 [1.33, 6.58].
CONCLUSIONS: Sarcopenia is a risk factor for increased incidence of complications (CTCAE > 2) after undergoing gastric and colorectal ESD, increased pneumonia rates, and higher mortality rates within five years following gastric ESD treatment in elderly patients. However, sarcopenia does not lead to an increased perforation rate in elderly patients undergoing gastric and colorectal ESD treatments. Registration and protocol: The protocol for this study was registered on the Open Science Framework in 2024 https://doi.org/10.17605/OSF.IO/7B2CZ . We also conducted pre-registration on PROSPERO (CRD42024532547).